Human study PLS-00138

Association Between Thymosin β4 and Coronary Arterial Lesions in Children with Kawasaki Disease.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Association Between Thymosin β4 and Coronary Arterial Lesions in Children with Kawasaki Disease.primary · Journal of inflammation research · 2025-07-03 · PMID 40631047 · DOI

Design and participants

Design: Case-control study
Population: Children with Kawasaki disease, with and without coronary artery lesions, and age-matched healthy controls
Conditions: Kawasaki disease, Coronary artery lesions
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): Serum Tβ4 was lower in children with Kawasaki disease, especially those with coronary artery lesions, and rose after IVIG. The authors suggest Tβ4 may be involved in KD inflammation and could be a diagnostic or therapeutic target.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: The study measured endogenous serum Tβ4 as a biomarker. It did not administer Tβ4, so it gives no evidence on the effects of the compound as an intervention.
abstract only: Only the abstract is available in the record. Sample sizes, numeric results and methods details are not reported.
confounding: This is an observational case-control comparison. Correlations of Tβ4 with cytokines may reflect disease activity rather than any causal role.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 40631047, abstract (Conclusion, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 40631047, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
limitations: PMID 40631047, abstract (Methods and Results) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 40631047, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).